Poly (ADP-ribose)-polymerase (PARP) inhibitors (PARPi) selectively kill tumour cells with impaired homologous recombination and are approved for use in homologous recombination-defective breast, ovarian, pancreatic and prostate cancers1. Here, PARP1 is linked to neoplasm.